Introduction Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered The present review assesses the principal pharmacological strategies that have been tested for an HIV cure starting from the in vitro proof of concept and the potential rationale of their in vivo applicability. We evaluated the possible pharmacological procedures employed during the early-stage HIV infection and the possibility of cART-free remission. We then analysed the shock and kill approach from the single compounds in vitro mechanism of action, to the in vivo application of single or combined actions. Finally, we briefly considered the novel immunological branch through the discovery and development of broadly neutralizing antibodies in regard of the current and future in vivo therapeutic strategies aiming to verify the clinical applicability of these compounds. Expert opinion Despite an incredible effort in HIV research cure, the likelihood of completely eradicating HIV is unreachable within our current knowledge. A better understanding of the mechanism of viral latency and the fully characterization of HIV reservoir are crucial for the discovery of new therapeutic targets and novel pharmacological entities.

Clinical pharmacology in HIV cure research : what impact have we seen? / A. Giacomelli, S. de Rose, S. Rusconi. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - (2018). [Epub ahead of print] [10.1080/17512433.2019.1561272]

Clinical pharmacology in HIV cure research : what impact have we seen?

A. Giacomelli;S. Rusconi
2018

Abstract

Introduction Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered The present review assesses the principal pharmacological strategies that have been tested for an HIV cure starting from the in vitro proof of concept and the potential rationale of their in vivo applicability. We evaluated the possible pharmacological procedures employed during the early-stage HIV infection and the possibility of cART-free remission. We then analysed the shock and kill approach from the single compounds in vitro mechanism of action, to the in vivo application of single or combined actions. Finally, we briefly considered the novel immunological branch through the discovery and development of broadly neutralizing antibodies in regard of the current and future in vivo therapeutic strategies aiming to verify the clinical applicability of these compounds. Expert opinion Despite an incredible effort in HIV research cure, the likelihood of completely eradicating HIV is unreachable within our current knowledge. A better understanding of the mechanism of viral latency and the fully characterization of HIV reservoir are crucial for the discovery of new therapeutic targets and novel pharmacological entities.
HIV; eradication; pharmacology; shock and kill
Settore MED/17 - Malattie Infettive
2018
20-dic-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
IERJ_A_1561272_O.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 920.15 kB
Formato Adobe PDF
920.15 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/608583
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact